<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Agalsidase alfa (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Agalsidase alfa (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Agalsidase alfa (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11013" href="/d/html/11013.html" rel="external">see "Agalsidase alfa (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52868867"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Replagal</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F4803327"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme</li></ul></div>
<div class="block doa drugH1Div" id="F4803359"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedication with an antipyretic (eg, acetaminophen), antihistamines, and/or corticosteroids should be considered; premedication is typically given 1 to 24 hours (prior to subsequent infusions in patients with a history of infusion-related reactions requiring symptomatic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mehta.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mehta.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2806c8e7-5d91-4e7a-86c0-5f6f8f68f985">Fabry disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fabry disease:</b> IV: 0.2 mg/kg every 2 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991980"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989162"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; has not been studied</p></div>
<div class="block doe drugH1Div" id="F4803360"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">No data available. Safety and efficacy have not been established.</p></div>
<div class="block dop drugH1Div" id="F4803358"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedication with oral antihistamines and corticosteroids may alleviate infusion-related reactions associated with agalsidase alfa.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2806c8e7-5d91-4e7a-86c0-5f6f8f68f985">Fabry disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fabry disease:</b> Children ≥7 years and Adolescents: IV: Refer to adult dosing.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F4803336"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (27%), flushing (12%), palpitations (15%), peripheral edema (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (26%), diarrhea (42%), nausea (42%), vomiting (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (9% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (33%), fatigue (31%; fatigue aggravated: 16%), headache (63%), hypoesthesia (15%), neuralgia (27%), pain (25%), paresthesia (30%), rigors (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (33%), asthenia (21%), back pain (32%), limb pain (40%), myalgia (20%), swelling of extremities (11%), tremor (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (14%; tinnitus aggravated: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (40%), dyspnea (18%), nasopharyngitis (50%), pharyngitis (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (38%), infusion related reaction (14%; more common in children &amp; adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (2%), chest tightness (7%), hypertension (8%), hypotension (5%), livedo reticularis (1%), tachycardia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (7%), erythema of skin (6%), pruritus (6%), rash at injection site (1%), urticaria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (2%), dysgeusia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reactions (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Feeling hot (5%), hypersomnia (2%), local discomfort (2%), malaise (8%), sensation of cold (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Joint swelling (8%), musculoskeletal pain (discomfort: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Increased lacrimation (2%), reduced blinking (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (10%), hoarseness (3%), increased bronchial secretions (1%), pharyngeal edema (6%), rhinorrhea (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, ischemic heart disease, oxygen saturation decreased, tachyarrhythmia, ventricular premature contractions</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell, feeling of heaviness</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Severe infusion related reaction</p></div>
<div class="block coi drugH1Div" id="F4803332"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity to agalsidase alfa or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F4803333"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of antidrug antibodies to recombinant agalsidase alfa is common, including patients naive to agalsidase alfa and those who previously received other enzyme replacement therapy (eg, agalsidase beta). In many of the patients with antidrug antibodies, presence of neutralizing antibodies was also detected on at least one occasion in an open-label safety study. Antidrug antibodies, including neutralizing antibodies, may be transient or persistent (Khan 2021). The presence of antidrug antibodies is usually observed following approximately 6 to 12 months of therapy. Further studies are needed to determine the clinical significance, if any, of antidrug antibodies (neutralizing and nonneutralizing) (Lenders 2018a; Lenders 2018b; Mauhin 2018; Mehta 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported with agalsidase alfa use. Discontinue therapy immediately for hypersensitivity reaction and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion reactions are common. Typically, infusion-related reactions are mild and characterized by fever, rigors, headache, dyspnea, nausea/vomiting, flushing, and fatigue. However, severe infusion reactions may occur, including angioedema, severe dyspnea with bronchospasm, throat tightness, urticaria, and cardiac events (tachycardia, hypo-/hypertension). Reactions generally occur within 2 to 4 months after therapy initiation although a later onset (ie, after 1 year) has also been observed. Infusion-related reactions usually diminish in frequency over time and can be attenuated with premedication. Depending on the severity of the reaction, the infusion may be temporarily interrupted (5 to 10 minutes) until the acute reaction subsides, or corticosteroids should be considered, particularly to prevent subsequent reactions in patients with a history of reactions. If severe allergic or anaphylactic-type reactions occur, immediate discontinuation is recommended (Khan 2021; Mehta 2022; Nicholls 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Patients with Fabry disease are at risk for progressive kidney failure due to the natural progression of the untreated disease; however, enzyme replacement therapy (eg, agalsidase alfa, agalsidase beta) may lessen the decline of kidney function (Feriozzi 2012; Khan 2021). Dosage adjustment is not necessary in patients with kidney impairment. According to the manufacturer’s labeling, impaired kidney function (eGFR &lt;60 mL/minute) may limit the renal response to enzyme replacement therapy potentially due to irreversible pathological changes.</p></div>
<div class="block prod-avail drugH1Div" id="F11216688"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040748"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52868868"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Replagal: 1 mg/mL (3.5 mL)</p></div>
<div class="block adm drugH1Div" id="F4803363"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Must be diluted further prior to infusion; do not administer undiluted. Infuse IV over 40 minutes using a dedicated IV line with filter. Do not infuse other agents through same IV line. Interrupt infusion in the presence of infusion-related reactions; infusion may be restarted after 5 to 10 minutes if symptoms are mild and subside.</p></div>
<div class="block admp drugH1Div" id="F52617407"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Must be diluted further prior to infusion; do not administer undiluted. Infuse IV over 40 minutes using a dedicated IV line with filter. Do not infuse other agents through same IV line. Interrupt infusion in the presence of infusion-related reactions; infusion may be restarted after 5 to 10 minutes if symptoms are mild and subside.</p></div>
<div class="block use drugH1Div" id="F4803329"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fabry disease:</b> Enzyme replacement therapy for Fabry disease (alpha-galactosidase A deficiency; Anderson-Fabry disease).</p></div>
<div class="block mst drugH1Div" id="F4803319"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Agalsidase alfa may be confused with agalsidase beta, alglucosidase alfa.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298691"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F4803343"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May diminish the therapeutic effect of Agalsidase Alfa.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: May diminish the therapeutic effect of Agalsidase Alfa.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gentamicin (Systemic): May diminish the therapeutic effect of Agalsidase Alfa.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May diminish the therapeutic effect of Agalsidase Alfa.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F4803330"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies. Information related to use in pregnancy is limited (Kalkum 2009; Senocak Tasci 2015).</p></div>
<div class="block brc drugH1Div" id="F21096298"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if agalsidase alfa is excreted into breast milk. The manufacturer recommends using with caution in breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F56796805"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of infusion-related reactions (eg, fever, rigors, tachycardia, hyper-/hypotension, dyspnea).</p></div>
<div class="block pha drugH1Div" id="F4803350"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Agalsidase alfa is a recombinant form of the enzyme alpha-galactosidase-A, which catalyzes the hydrolysis of globotriaosylceramide (Gb-3), cleaving a terminal galactose residue from the molecule. Accumulation of globotriaosylceramide (Gb-3) may occur within the tissues of patients with Fabry disease. Agalsidase has been noted to reduce cellular levels of Gb-3 in many cell types including endothelial and parenchymal.</p></div>
<div class="block phk drugH1Div" id="F4803352"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: In a study of 17 adult males, median V<sub>d</sub> was 203 mL/kg (range: 89 to 6,778 mL/kg); in 14 pediatric patients, mean V<sub>d</sub> was 128 mL/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Plasma; via peptide hydrolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: In a study of 17 adult males, median half-life was 54.7 minutes (range: 28.5 to 654.2 minutes); in 14 pediatric patients, mean half-life was 32 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50781770"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Replagal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22246281">
<a name="22246281"></a>Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M; FOS Investigators. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. <i>Clin J Am Soc Nephrol</i>. 2012;7(1):60-69. doi:10.2215/CJN.03130411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/22246281/pubmed" id="22246281" target="_blank">22246281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19233535">
<a name="19233535"></a>Kalkum G, Macchiella D, Reinke J, et al. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease. <i>Eur J Obstet Gynecol Reprod Biol.</i> 2009;144(1):92-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/19233535/pubmed" id="19233535" target="_blank">19233535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34542871">
<a name="34542871"></a>Khan A, Sirrs SM, Bichet DG, et al; Canadian Fabry Disease Initiative. The safety of agalsidase alfa enzyme replacement therapy in Canadian patients with Fabry disease following implementation of a bioreactor process. <i>Drugs R D</i>. 2021;21(4):385-397. doi:10.1007/s40268-021-00361-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/34542871/pubmed" id="34542871" target="_blank">34542871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30385651">
<a name="30385651"></a>Lenders M, Neußer LP, Rudnicki M, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. <i>J Am Soc Nephrol</i>. 2018a;29(12):2879-2889. doi:10.1681/ASN.2018070740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/30385651/pubmed" id="30385651" target="_blank">30385651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30268124">
<a name="30268124"></a>Lenders M, Schmitz B, Brand SM, Brand E. Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact? <i>Orphanet J Rare Dis</i>. 2018b;13(1):171. doi:10.1186/s13023-018-0916-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/30268124/pubmed" id="30268124" target="_blank">30268124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25933799">
<a name="25933799"></a>Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. <i>J Am Soc Nephrol</i>. 2016;27(1):256-264. doi:10.1681/ASN.2014121226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/25933799/pubmed" id="25933799" target="_blank">25933799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30064518">
<a name="30064518"></a>Mauhin W, Lidove O, Amelin D, et al. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. <i>Orphanet J Rare Dis</i>. 2018;13(1):127. doi:10.1186/s13023-018-0877-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/30064518/pubmed" id="30064518" target="_blank">30064518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehta.1">
<a name="Mehta.1"></a>Mehta A, Beck M, Sunder-Plassmann G, eds. <i>Fabry Disease: Perspectives from 5 Years of FOS</i>. Barbey F, Livio F. Chapter 41: Safety of enzyme replacement therapy. Oxford: Oxford PharmaGenesis; 2006. <a href="https://www.ncbi.nlm.nih.gov/books/NBK11617/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK11617/</a>. Accessed February 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23430925">
<a name="23430925"></a>Nicholls K, Bleasel K, Becker G. Severe infusion reactions to Fabry enzyme replacement therapy: rechallenge after tracheostomy. <i>JIMD Rep</i>. 2012;5:109-12. doi:10.1007/8904-2011-106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/23430925/pubmed" id="23430925" target="_blank">23430925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Replagal.2020.05">
<a name="Replagal.2020.05"></a>Replagal (agalsidase alfa) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338166">
<a name="26338166"></a>Senocak Tasci E, Bicik Z. Safe and successful treatment with agalsidase beta during pregnancy in Fabry disease. <i>Iran J Kidney Dis</i>. 2015;9(5):406-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-alfa-united-states-not-available-drug-information/abstract-text/26338166/pubmed" id="26338166" target="_blank">26338166</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8515 Version 111.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
